Drugs / TML-6
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06562114 | Jul 2024 → Jul 2025 | — | Merry Life Biomedical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07612150 | Aug 2026 → Apr 2028 expected | Alzheimer disease | Merry Life Biomedical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TML-6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562114 ↗ |
| Modality | Small molecule | “it is an investigational oral small molecule” NCT07612150 ↗ |
| Route | Oral | “Administered orally” NCT06562114 ↗ |